Detalles de la búsqueda
1.
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
Gut
; 2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38609165
2.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883053
3.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33798499
4.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34863358
5.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34370971
6.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33306989
7.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617777
8.
SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures.
Thorax
; 77(3): 259-267, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34737194
9.
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol.
Thorax
; 77(6): 606-615, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34810237
10.
Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial.
JAMA
; 327(6): 546-558, 2022 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35072713
11.
Measles Vaccine Coverage and Disease Outbreaks: A Systematic Review of the Early Impact of COVID-19 in Low and Lower-Middle Income Countries.
Int J Public Health
; 69: 1606997, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38725903
12.
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Nat Commun
; 15(1): 924, 2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38296965
13.
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
J Infect
; 86(6): 574-583, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37028454
14.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085049
15.
Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.
mSphere
; 7(1): e0067421, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35080470
16.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis
; 22(8): 1131-1141, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35550261
17.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
J Infect
; 84(6): 795-813, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405168
18.
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Lancet Respir Med
; 10(11): 1049-1060, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35690076
19.
The Volunteers in Research programme: supporting COVID-19 research and improving medical training in parallel.
Clin Med (Lond)
; 21(3): 182-188, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34001569
20.
Multi-modality detection of SARS-CoV-2 in faecal donor samples for transplantation and in asymptomatic emergency surgical admissions.
F1000Res
; 10: 373, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34367617